# Epic Sciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/epic-sciences

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.epicsciences.com
- Total disclosed funding: $223M
- Latest round: Series G (Apr 14, 2023)
- Investors on record: 20

## About

Epic Sciences Inc., based in the US, is dedicated to advancing precision medicine through innovative cancer diagnostics, leveraging proprietary technologies to enhance patient outcomes.Epic Sciences Inc. is a cancer diagnostics company that specializes in developing technologies for analyzing circulating tumor cells. Founded in 2008, it is headquartered in San Diego, US. The company has completed 10 funding deals, with its latest funding round being Series G, amounting to USD 24.00 mn, bringing the total amount raised to USD 24.00 mn and a current company valuation of USD 243.33 mn. The company was established by Peter Kuhn, who has a history of involvement in advancing scientific technologies.Epic Sciences primarily offers innovative diagnostic solutions aimed at improving cancer treatment decisions. Its flagship product employs advanced analytics to detect and characterize circulating tumor cells, addressing critical challenges in cancer diagnostics and treatment personalization. The company serves various healthcare providers, including hospitals and oncology practices, predominantly in North America, Europe, and Asia-Pacific, providing tailored solutions to meet the specific needs of these markets.Epic Sciences operates on a revenue model centered around service contracts for its diagnostic solutions, where healthcare providers pay for access to its technologies. The revenue structure includes income from consulting services that assist clients in implementing and optimizing their diagnostic strategies. The pricing plans are structured to cater to different service levels, ensuring secure cash flow through long-term agreements with clients.Epic Sciences aims to expand its product offerings, with plans to launch new diagnostic tools in the coming year, targeting enhanced patient monitoring capabilities. The company is also focusing on entering new geographic markets, specifically targeting expansion into Europe and Asia by 2025. The recent funding from the Series G round will be utilized to support these initiatives, facilitating research and development as well as market entry strategies.

## Funding rounds

- Series G, Apr 14, 2023, $24M — Arsenal Capital Partners, Domain Associates, Deerfield Management, Blue Ox Healthcare Partners, LabCorp Ventures
- Series F, May 18, 2022, $60M — Arsenal Capital Partners, Laboratory Corporation of America Holdings, Deerfield Management, Blue Ox Healthcare Partners
- Series E, Jun 21, 2018, $53M — Domain Associates, Alexandria Venture Investments, Varian Medical Systems, Inc., Genomic Health, Inc., Deerfield Management, Sabby Capital, Blue Ox Healthcare Partners, Virtus Inspire Ventures, Altos Capital Partners
- Series D, Apr 28, 2017, $40M — Domain Associates, Genomic Health, Inc., RMI Partners, Sabby Capital, Hermed Capital, Virtus Inspire Ventures, Pagoda Innovation, Altos Capital Partners, Reach Tone Limited
- Series C, Jul 30, 2014, $30M — Domain Associates, Arcus Ventures, Roche Venture Fund, Pfizer Venture Investments, RMI Partners
- Series B, Nov 13, 2012, $13M — Domain Associates, Roche Venture Fund, Pfizer Venture Investments
- Series A, Jun 30, 2009, $2.5M — Venrock

## Investors

- Venrock (https://capitalatlas.ai/funds/venrock) — Series A
- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series B, Series C, Series D, Series E, Series G
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series B, Series C
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series B, Series C
- Arcus Ventures (https://capitalatlas.ai/funds/arcus-ventures) — Series C
- RMI Partners (https://capitalatlas.ai/funds/rmi-partners) — Series C, Series D
- Genomic Health, Inc. — Series D, Series E
- Sabby Capital (https://capitalatlas.ai/funds/sabby-capital) — Series D, Series E
- Hermed Capital (https://capitalatlas.ai/funds/hermed-capital) — Series D
- Virtus Inspire Ventures (https://capitalatlas.ai/funds/virtus-inspire-ventures) — Series D, Series E
- Pagoda Innovation (https://capitalatlas.ai/funds/pagoda-innovation) — Series D
- Altos Capital Partners (https://capitalatlas.ai/funds/altos-capital-partners) — Series D, Series E
- Reach Tone Limited (https://capitalatlas.ai/funds/reach-tone-limited) — Series D
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series E
- Varian Medical Systems, Inc. — Series E
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series E, Series F, Series G
- Blue Ox Healthcare Partners (https://capitalatlas.ai/funds/blue-ox-healthcare-partners) — Series E, Series F, Series G
- Arsenal Capital Partners (https://capitalatlas.ai/funds/arsenal-capital-partners) — Series F, Series G
- Laboratory Corporation of America Holdings — Series F
- LabCorp Ventures (https://capitalatlas.ai/funds/labcorp-ventures) — Series G